Proceedings of the National Academy of Sciences · 2012 · 161 citations · 28 references
Veterinary MedicineImmunologyPharmacologyImmunopathologyInflammationInnate ImmunityChronic Obstructive Pulmonary DiseaseInflammatory BiomarkersMucosal InflammationObstructive Lung DiseasePulmonary InflammationRespiratory DiseaseAirway Epithelial FunctionAirway Epithelial InjuryChronic Lung InflammationChronic Obstructive Pulmonary Disease InflammationNeutrophilic InfiltratesNeutrophilic Lung InflammationProinflammatory MediatorsSerum Amyloid A Protein
Chronic obstructive pulmonary disease (COPD) will soon be the third most common cause of death globally. Despite smoking cessation, neutrophilic mucosal inflammation persistently damages the airways and fails to protect from recurrent infections. This maladaptive and excess inflammation is also refractory to glucocorticosteroids (GC). Here, we identify serum amyloid A (SAA) as a candidate mediator of GC refractory inflammation in COPD. Extrahepatic SAA was detected locally in COPD bronchoalveolar lavage fluid, which correlated with IL-8 and neutrophil elastase, consistent with neutrophil recruitment and activation. Immunohistochemistry detected SAA was in close proximity to airway epithelium, and in vitro SAA triggered release of IL-8 and other proinflammatory mediators by airway epithelial cells in an ALX/FPR2 (formyl peptide receptor 2) receptor-dependent manner. Lipoxin A(4) (LXA(4)) can also interact with ALX/FPR2 receptors and lead to allosteric inhibition of SAA-initiated epithelial responses (pA(2) 13 nM). During acute exacerbation, peripheral blood SAA levels increased dramatically and were disproportionately increased relative to LXA(4). Human lung macrophages (CD68(+)) colocalized with SAA and GCs markedly increased SAA in vitro (THP-1, pEC(50) 43 nM). To determine its direct actions, SAA was administered into murine lung, leading to induction of CXC chemokine ligand 1/2 and a neutrophilic response that was inhibited by 15-epi-LXA(4) but not dexamethasone. Taken together, these findings identify SAA as a therapeutic target for inhibition and implicate SAA as a mediator of GC-resistant lung inflammation that can overwhelm organ protective signaling by lipoxins at ALX/FPR2 receptors.
28
Shao Bo Su, Wanghua Gong, Ji‐Liang Gao et al. · The Journal of Experimental Medicine · 1999 · 428 citations · Full text
Sarah V. Culpitt, Duncan F. Rogers, Pallav L. Shah et al. · American Journal of Respiratory and Critical Care Medicine · 2002 · 338 citations